ELTX News & Events

Latest data shows the largest indicative borrow rate increases among liquid option names include: Amplitech Group Inc (AMPG) 90.12% +3.72, Sleep Number (SNBR) 114.25% +2.32, Momentus (MNTS) 52.16% +1.96, Angion Biomedica Corp (ELTX) 26.32% +1.72, OPTU Stock (OPTU) 3.55% +0.72, Defiance 1.75x MSTR ETF (MSTX) 20.02% +0.71, Cardiff Oncology (CRDF) 50.29% +0.53, Sellas Life Sciences (SLS) 13.25% +0.46, Autobot Holdings (ARBE) 4.39% +0.43, and Alpha Tau Medical Ltd (DRTS) 9.02% +0.36.

Elicio Therapeutics reported preliminary clinical observations from its recently completed Phase 2 AMPLIFY-7P study of its cancer immunotherapy, ELI-002 7P. Three patients who experienced disease progression after treatment subsequently achieved confirmed complete radiographic and complete metabolic responses after receiving a subsequent nivolumab-based therapy. Subject to funding, Elicio plans to initiate a Phase 1 study evaluating ELI-002 7P in combination with chemotherapy and a checkpoint inhibitor in metastatic pancreatic cancer. "Three complete responses observed following subsequent nivolumab-based therapy are particularly intriguing because complete, durable tumor responses in this setting are historically rare," said Robert Connelly, president and CEO of Elicio Therapeutics. "These observations suggest that ELI-002-induced immune priming may synergize with other therapies to enable tumor eradication, supporting prospective evaluation of ELI-002 7P in combination with checkpoint inhibition."